Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers

Cuiping Wang, Yang Sun, Huanwen Wu, Dachun Zhao & Jie Chen
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tsinghua University, Beijing, China

Date of submission 17 May 2013
Accepted for publication 9 September 2013
Published online Article Accepted 14 September 2013

Wang C, Sun Y, Wu H, Zhao D & Chen J
(2014) Histopathology 64, 567–576
Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers

Aims: To determine clinicopathological criteria and molecular markers helpful in distinguishing adrenocortical carcinomas (ACCs) from adrenocortical adenomas (ACAs).

Methods and results: We analysed retrospectively the clinical and pathological features of 50 adrenal cortical tumours, and tested the expression of miR483-3p by in-situ hybridization as well as the expression of IGF2 and Smad4 by immunohistochemistry. We found that tumour size, tumour weight, hormonal function and the Weiss system are all high-efficacy criteria for differentiating malignant from benign tumours (P < 0.001). MiR483-3p was overexpressed in 68% (17 of 25) of ACCs compared to 12% (three of 25) of ACAs (P < 0.05). Using a combination of miR483-3p and Smad4 improved diagnostic accuracy. Molecular markers were then tested in an independent set of 15 borderline tumours. We confirmed that the combined use of miR483-3p and Smad4 immunochemistry can complement the Weiss score in the diagnosis of ACC in cases that display borderline histology.

Conclusions: Tumour size, tumour weight, hormonal function and the Weiss system are useful clinicopathological criteria that can result in accurate diagnosis of most ACCs and ACAs. In challenging cases, miR483-3p and Smad4 expression may help in distinguishing these two entities.

Keywords: adrenal cortical tumours, clinicopathological features, differentiation, diagnosis, hsa-mir-483-3p, in-situ hybridization

Introduction

Adrenal masses are among the most frequent tumours in humans. A vast majority of these tumours are benign, and only a small subset of adrenal masses are malignant adrenocortical carcinomas (ACCs). ACC is a rare but very aggressive cancer. It affects one to two people per million per year and accounts for 0.02–0.2% of all cancer deaths. An accurate diagnosis is critical, because the prognosis, follow-up and therapeutic strategy for ACC are very different to those for a benign tumour. However, it is difficult in some cases to distinguish malignant from benign cortical tumours accurately through clinical characteristics or histopathological criteria. The Weiss system, including nine-point histopathological criteria, is currently the most commonly used method for assessing malignancy. The original threshold for malignancy, established in 1984, was the presence of at least four criteria; but this was reduced to three or more criteria in 1989 after it was observed that some tumours with a score of 3 had recurred. In 2002, Aubert et al. proposed a modification of the Weiss system; the two systems correlated significantly, and in both the threshold for malignancy is a total score of 3. However, the Weiss system was found to be less specific, as several studies noted that...
some tumours with a Weiss score of 3 had a clinical benign course, and that individual tumours may behave in a malignant manner despite initially receiving a Weiss score of 2. Therefore, there is a need for a comprehensive understanding of the clinical and morphological characteristics of adrenocortical tumours, and the identification of reliable biomarkers as an adjunct to routine pathological analysis.

MicroRNAs (miRNAs) are endogenous, non-coding RNA of approximately 22 nucleotides that regulate gene expression by controlling target mRNA translation or degradation. Angelo et al. reported that miR483-3p is overexpressed in human breast, colon and liver cancers, suggesting a wide involvement of this miRNA in human tumorigenesis. However, its expression and the mechanisms underlying this expression in adrenocortical tumours are unclear.

The gene encoding Smad4/DPC4, a critical effector in the TGF-β signalling pathway, has been reported to be a target for miR483-3p in some studies, but the role of this effector in adrenal cortical tumours has not been established definitively. MiR483 is expressed from intron 2 of the IGF2 gene, and several studies have identified that up-regulation of IGF2 expression is the dominant change in malignant adrenocortical tumours.

In this study, we analysed clinical and pathological features of adrenal cortical tumours and investigated the expression of miR483-3p and its association with IGF2 and Smad4 in ACCs, in order to develop a theoretical basis for differential diagnosis, prognostic evaluation and molecular target therapy.

Materials and methods

Patients and tumour samples

Samples of adrenal tumour were collected from patients undergoing adrenalectomy at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, from July 2001 to July 2012. This study was approved by the Peking Union Medical College Hospital Ethics Committee. Twenty-five malignant tumours were available and used as experimental samples, and 25 benign tumours selected randomly from 1564 patients with adrenocortical adenomas (ACAs) were used as control samples. All 50 tumours had full clinical and pathological data. The follow-up period was 6–123 months.

The Weiss system was applied to all 50 adrenal cortical tumours separately by two independent observers (H.W. and J.Z.) blinded to the clinical courses of the patients. A consensual Weiss score was established on a multiheaded light microscope. The nine Weiss histopathological criteria of malignancy were defined according to Aubert et al.

An independent set of 15 borderline adrenal cortical tumours (Weiss score = 2 or 3) were used to validate further the diagnostic accuracy of the molecular markers. The morphological features of the 15 cases are summarized in Table S1.

In-situ hybridization

A miRCURY LNA detection probe for human mature miR483-3p (5’- AAGACGGAGAGAGATGA-3’), U6-positive control and the scrambled negative control, which were all 5’-digoxigenin- and 3’-digoxigenin-labelled, were purchased from Exiqon (Vedbaek, Denmark). Detection of miR483-3p by in-situ hybridization using the oligonucleotide probes was performed according to the manufacturer’s instructions. Briefly, human tissues were deparaffinized, treated with proteinase K, washed in sterile diethylpyrocarbonate-treated phosphate-buffered saline (PBS), and subsequently fixed with 4% paraformaldehyde. After prehybridization at room temperature followed by incubation at 61°C separately for 1 h, hybridization was performed at 61°C for 21 h, followed by a wash in ×2 standard saline citrate and 3 × 30-min washes at 61°C in ×1 standard saline citrate and 50% formamide. After blocking (2% sheep serum and 2 mg/ml bovine serum albumin in PBS with Tween-20) at room temperature for 1 h, the blocking buffer was replaced with blocking buffer containing anti-digoxigenin-alkaline phosphatase (Cat. no. 11 093 74910, 150U, 200 µl, 1:500; Roche, Basel, Switzerland), and all slides were then placed into a ddH2O box and incubated at 4°C overnight. The next day, the slides were washed in PBS with Tween-20 for 7 × 5 min at room temperature, equilibrated, NBT/BCIP added (Cat. no. 11 681 451 001, 8 ml, 1:500, Roche), and incubated for 3 h in the dark at room temperature for visualization.

The slides were then scored independently by two pathologists (H.W. and Y.S.) as negative (−), weak or focally positive (1+) or strongly positive (2+).

Immunohistochemistry

Immunohistochemical detection of IGF2, Smad4 and MIB-1 was performed on standard sections of paraffin-embedded tissue, which were cut at a 4-µm thickness and mounted on positively charged slides (SuperFrost Plus; Fisher Scientific, Loughborough, UK). After being conventionally deparaffinized and rehydrated, the sections were treated separately in 10 µs citrate buffer.
(pH 6.0) for 5 min for IGF2 and MIB-1, and in EDTA buffer (pH 8.0) for 10 min for Smad4, at 121°C in an autoclave for antigen retrieval. The sections were then immersed in ddH2O containing 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity, followed by incubation with 10% goat serum to block non-specific antibody binding sites. Sections were incubated at 4°C overnight with anti-IGF2 goat polyclonal antibody (sc-1415; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted at 1:100, anti-MIB-1 monoclonal antibody working liquid (ZM-0167, ZSGB-BIO, China), or anti-Smad4 rabbit monoclonal antibody (ab40759; Abcam, Cambridge, MA, USA) diluted at 1:100. Appropriate positive and negative controls were employed. Scoring of IGF2 staining was graded semiquantitatively from 0 to 4,19,20 and Smad4 staining assessed as ‘diffusely positive’, ‘focally positive’ or ‘negative’, independently by two observers (H.W. and Y.S.).21 Discordant cases were reviewed on a multi-headed light microscope for discussion and consensus.

**SCORING FOR IN-SITU HYBRIDIZATION AND IMMUNOHISTOCHEMISTRY**

For the purposes of our analysis, we dichotomized staining scores as negative/low versus elevated. For miR483-3p and Smad4, elevated included only ‘strongly positive’ or ‘diffusely positive’ cases. For IGF2, elevated was regarded as an immunoscore ≥3.

**STATISTICAL ANALYSES**

Comparisons of frequencies and correlations between clinicopathological features, cellular proliferative activity and miR483-3p, IGF2 or Smad4 expression were undertaken using Pearson’s χ² test or Fisher’s exact test. Comparisons of the means were performed using Wilcoxon’s rank sum tests. Survival curves were plotted using the Kaplan–Meier method and P-values were calculated using the log-rank test. The length of overall survival (OS) was defined as the period from the date of surgery to the date of death as a result of the tumour or the latest follow-up. All statistical analyses were performed with SPSS software (SPSS version 17.0; SPSS, Inc., Chicago, IL, USA). A P-value < 0.05 was considered statistically significant.

**Results**

**CLINICAL FEATURES**

The clinical data for both malignant and benign adrenocortical tumours are summarized in Table 1. There was no statistical difference in sex, age and tumour location between the patients with malignant and benign tumours. However, malignant tumours were significantly larger and heavier than benign tumours (P < 0.001). Moreover, patients presenting with primary aldosterone syndrome were more likely to have a benign tumour (P < 0.001; Table 1).

Among the patients with a malignant tumour, 13 recurred (local recurrence and/or metachronous distant metastasis) during follow-up. Moreover, 14 died from the cancer (mean OS: 23.1 months), two continue to live with the disease, three were alive and disease-free.

### Table 1. Clinical parameters of the 50 patients with adrenocortical tumors

| Sex            | Malignant (n = 25) | Benign (n = 25) | P value |
|----------------|-------------------|----------------|---------|
| Male           | 11                | 11             | 1.000   |
| Female         | 14                | 14             |         |
| Tumor location |                   |                |         |
| Right          | 13                | 13             | 0.879   |
| Left           | 12                | 11             |         |
| Bilateral      | 0                 | 1              |         |
| Endocrinic syndrome |            |                |         |
| Cushing syndrome | 7               | 3              |         |
| Primary aldosterone syndrome | 1 | 12             | <0.001*
| Sex characteristics abnormality | 3 | 0              |         |
| Non-functioning | 14               | 10             |         |
| Age (years)    |                   |                |         |
| Mean           | 44.4              | 48.6           | 0.229   |
| Range          | 18–75             | 34–69          |         |
| Tumor size (cm)|                   |                |         |
| Mean           | 11.5              | 2.4            | <0.001  |
| >6.5           | 17                | 0              | <0.001  |
| Tumor weight (g)|            |                |         |
| Mean           | 558.0             | 6.7            | <0.001  |
| >50            | 21                | 0              | <0.001  |

*P value for comparisons of frequencies between malignant and benign tumors presenting with primary aldosterone syndrome.
free at their last follow-up and six were lost to follow up. Among patients with a benign tumour, eight were lost to follow up and 17 were alive and disease-free after their operations (mean follow-up: 57 months).

**Pathological Features**

The Weiss scores for the 25 benign tumours were all equal to or less than 2. No case of malignancy scored less than 4. The mean Weiss score was significantly higher for malignant tumours than benign tumours ($P < 0.001$). Each of the Weiss criteria was observed more frequently in malignant tumours ($P < 0.05$). In our study, the diagnostic efficacy of Weiss scores $\geq 3$ was high for malignancy, with 100% specificity and 100% sensitivity overall. The most sensitive criterion was ‘mitotic rate $>5/50$ HPF’ (100%), and the least sensitive criteria were ‘$\leq 25\%$ clear cells’ or ‘sinusoid invasion’ (36.0%). The most specific criteria were ‘mitotic rate $>5/50$ HPF’ ‘necrosis’, ‘venous invasion’, ‘sinusoid invasion’ and ‘capsular invasion’ (100%), and the least was ‘Führman nuclear grade III/IV’ (68%; Table 2).

**Expression of MiR483-3p, IGF2 and Smad4**

MiR483-3p was overexpressed significantly in 68% (17 of 25) of ACCs compared to 12% (3 of 25) of ACAs ($P < 0.05$; Table 3, Figure 1A,D). Moreover, there was a positive correlation between expression of miR483-3p and IGF2 ($P < 0.05$; Figure 1A,B,E, Table S2). Although Smad4 showed statistically significantly lower expression in ACCs than in ACAs ($P < 0.05$; Table 3, Figure 1C,F), there was no negative relationship between expression of miR483-3p and Smad4 ($P > 0.05$; Table S2). Smad4 negative/low expression was sensitive in differentiating ACCs from ACAs (sensitivity = 92%), but with a low specificity of only 40%. However, the combination of negative/low Smad4 and elevated miR483-3p expression provided a diagnostic specificity of 92.8%.

**Correlation Between the Expression of MiR483-3p, IGF2 or Smad4 and Clinicopathological Variables in Adrenocortical Carcinomas**

We evaluated the relationship between the three markers and clinicopathological variables in ACCs. MiR483-3p overexpression was not associated with age, tumour size, tumour weight, hormonal function, recurrence, metastasis or Weiss scores, but there was a relationship with gender, as male patients were statistically more likely to overexpress miR483-3p than were females ($P < 0.05$; Table S3).

For IGF2, there was no relationship with any clinicopathological variables (Table S3). Regarding Smad4, there were only two patients with elevated Smad4 expression, and there were no specific correlations with the clinicopathological features (Table S4).

**Correlation Between MiR483-3p, IGF2 or Smad4 and Cellular Proliferative Activity in Adrenocortical Carcinomas**

Because the MIB-I labelling index has been shown to possess diagnostic and prognostic value in several studies,$^{20,22-25}$ we tested MIB-1 expression and analysed its relationship with miR483-3p, IGF2 and Smad4 expression using the same study cohort. According to previous studies,$^{24,25}$ a proliferation index $<5\%$ was considered to be low and a proliferation index $>5\%$ was considered to be high. Our results showed that MIB-1 was highly expressed in 64% (16 of 25) ACCs, compared to 4% (one of 25) of ACAs. However, the MIB-1 expression level was not associated with miR483-3p, IGF2 or Smad4 expression in ACCs (Table 4).

---

**Table 2. Weiss system for the 50 adrenocortical tumors**

|                  | Malignant ($n = 25$) | Benign ($n = 25$) | $P$ value |
|------------------|----------------------|------------------|-----------|
| Nuclear grade Fuhrman III/IV | 21                   | 8                | $<0.001$ |
| Mitotic rate $>5/50$ HPF | 25                   | 0                | $<0.001$ |
| Abnormal mitoses | 23                   | 2                | $<0.001$ |
| $\leq 25\%$ clear cells | 9                    | 3                | 0.047    |
| $>1/3$ diffuse architecture | 10                  | 1                | 0.002    |
| Necrosis        | 21                   | 0                | $<0.001$ |
| Venous invasion | 11                   | 0                | $<0.001$ |
| Sinusoid invasion | 9                    | 0                | 0.002    |
| Capsular invasion | 18                  | 0                | $<0.001$ |
| Total Weiss score (mean) | 5.76                | 0.56             | $<0.001$ |
To validate further the differential diagnostic efficacy of the molecular markers, their expression levels were evaluated in the 15 borderline tumours (Weiss score = 2 or 3). The results and the relationship with clinicopathological data are summarized in Table 5. The follow-up period was 42–103 months. Among the 15 borderline cases, three relapsed (local recurrence and/or metastasis) during follow-up, four were lost to follow up and the other eight were all alive and disease-free after their surgery. We found that none of the four markers alone could predict the malignant potential accurately. However, there are only four cases with both elevated miR483-3p and negative/low Smad4 expression. Notably, among these four cases, three recurred and died of disease (mean survival: 29.7 months) and one patient was lost to follow-up. Together, these results indicated that the combination of miR483-3p and Smad4 is useful in assisting the Weiss system in establishing a diagnosis in borderline cases.

Table 3. Expression of miR483-3p, IGF2 and Smad4 in adrenocortical tumors

|                  | Malignant (n = 25) | Benign (n = 25) | P value |
|------------------|--------------------|----------------|---------|
| miR483-3p        | Elevated 17, Negative/low 8 | Elevated 3, Negative/low 22 | <0.001  |
| IGF2             | Elevated 16, Negative/low 9 | Elevated 7, Negative/low 18 | 0.011   |
| Smad4            | Elevated 2, Negative/low 23 | Elevated 10, Negative/low 15 | 0.008   |

The differential diagnostic efficacy of the molecular markers in borderline tumours

We further validated the prognostic value of the combined use of miR483-3p and Smad4 immunohistochemistry in adrenocortical carcinomas. Only patients with sufficient follow-up data were included (19 of 25). The trend of the OS indicated that ACC patients with tumours showing elevated expression of miR483-3p and negative/low Smad4 had a worse disease outcome than other patients, but the association was not statistically significant (P = 0.053, Figure 2).

The prognostic value of miR483-3p and Smad4 in ACCs

We further validated the prognostic value of the combined use of miR483-3p and Smad4 immunohistochemistry in adrenocortical carcinomas. Only patients with sufficient follow-up data were included (19 of 25). The trend of the OS indicated that ACC patients with tumours showing elevated expression of miR483-3p and negative/low Smad4 had a worse disease outcome than other patients, but the association was not statistically significant (P = 0.053, Figure 2).

Discussion

Distinguishing malignant from benign adrenal cortical tumours represents a great challenge for both clinicians and pathologists. In 1974, Lewins et al. reported that the definitive evidence for malignancy was distant metastasis and/or local infiltration. However, with the development of imaging techniques, a growing number of unexplained adrenal incidentalomas have been found, making the diagnosis of potential malignancy more challenging in clinical practice. Therefore, the differential diagnosis of adrenal cortical carcinoma from adenoma requires comprehensive clinical characteristics, pathological morphological evaluation and a variety of auxiliary investigations.

Tumour weight and size have been important clues for malignancy. Tang and Grey demonstrated that tumour weights >95 g can be used to determine malignancy with 100% sensitivity. Aubert et al. determined that a tumour weight greater than 50 g predicted malignancy with 100% sensitivity and 90.9% specificity in a retrospective analysis of 49 adrenal masses, including 24 ACCs and 25 ACAs. Our study confirmed that malignant tumours had significantly larger sizes and greater weights than benign tumours. Furthermore, we determined that large tumours with a weight >50 g were malignant, with 100% specificity and 100% sensitivity. However, some studies have also reported tumours with a weight lower than 50 g following a malignant course. Tumour size is often underestimated by radiological investigation. Thresholds ranging from 3 to 6 are often used to predict the risk of malignancy, according to various studies. However, small thresholds are applied mainly to increase the preoperative radiological identification of non-functioning tumours. Aubert et al. proposed a threshold of larger than 6.5 cm for distinguishing malignancy with 100% sensitivity and 91.7% specificity. Somewhat differently, our retrospective study determined that a tumour size greater than 6.5 cm significantly predicted malignancy, with 68% sensitivity and 100% specificity. Further studies with larger sample sizes are needed to confirm the role of tumour weight and size in assessing adrenocortical malignancy. Moreover, in this retrospective study, patients presenting with primary aldosteronism were found to be
more likely to have a benign tumour than a malignant tumour.

Diagnosis of adrenal cortical carcinomas is not always straightforward. Lesions of intermediate size with some suspicious features are often equivocal for diagnosis. At this point, a large number of histological factors can be taken into account and several multiparametric systems have been proposed for
delineating malignancy. Among various histological criteria, the Weiss system is most commonly used. To evaluate its diagnostic efficacy further, this retrospective study reviewed the Weiss criteria among all 50 samples, revealing that a total Weiss score of 3 or higher predicted malignancy significantly, with 100% specificity and 100% sensitivity. However, it has been reported previously that some tumours with three Weiss criteria maintain a clinical benign course, and individual tumours with two Weiss criteria have behaved in a malignant manner during follow-up. Thus, although the Weiss system can result in accurate diagnosis of most ACCs and ACAs, it is not applicable in some challenging cases.

To date, many approaches have been studied for the distinction of benign and malignant adrenocortical tumours, such as genotyping methods, molecular profiling studies and most commonly immunohistochemical approaches. Numerous molecular markers, including topoisomerase II alpha, MiB-1, p53, E-cadherin, HER-2, p27 and the IGF family members, have been validated as diagnostic and prognostic indicators. Among these, in most studies the MiB-1/Ki-67 labelling index was shown to possess diagnostic and prognostic value. However, the diagnostic threshold used was not consistent, and diagnostic accuracy still requires confirmation in a larger sample size.

Biomarkers for accurate diagnosis, prognosis or molecular therapy are needed urgently. miRNA markers are ideal for this purpose because miRNAs seem to be more stable and less prone to degradation than mRNAs. Moreover, miRNAs are short, and can therefore be easily knocked down or overexpressed for therapy. In our study, locked nucleic acid in-situ hybridization was used to determine the expression of miR483-3p in both adrenal cortical carcinomas and adenomas. We found 17 cases of overexpression in 25 subjects with primary malignancies (68%) compared to three of 25 (12%) patients with benign tumours. In line with these results, Patterson et al. demonstrated that miR483-3p was highly expressed in ACCs by real-time quantitative RT–PCR in 34 samples (10 primary ACCs and 24 ACAs).

Previous studies have shown that altered expression of specific miRNAs can contribute to the initiation and progression of cancer. Our results indicate that miR483-3p is highly expressed in primary ACCs. Therefore, it leads us to hypothesize that miR483-3p may promote the development of adrenal cortical carcinomas. In addition, some experiments have demonstrated that miR483-3p can protect cells from apoptosis in liver and colorectal cancer cell lines. Future functional studies are necessary to assess whether miR483-3p plays a similar role in ACCs.

MiR483-3p is located at intron 2 of IGF2, which has been reported to be one of the most commonly overexpressed genes in ACCs. This suggests a high likelihood of co-expression. To test this hypothesis, we measured the expression of IGF2 in all 50 samples by immunohistochemistry. We found high expression of IGF2 in 16 of 25 ACCs (64%). Furthermore, 14 patients showed simultaneous high expression of miR483-3p and IGF2. There was a positive correlation between the expression of IGF2 and miR483-3p. Thus, the IGF2 gene not only exerts mitogenic effects through interactions with the IGF-I receptor (IGF-IR); it may also exploit miR483-3p to regulate target gene expression post-transcriptionally. However, a small subset of patients displayed divergent expression between miR483-3p and IGF2, thus revealing a mechanism in which IGF2 and miR483-3p are not co-regulated. This is an area that requires further investigation.

A recent study reported that the expression of Smad4/DPC4 was suppressed by miR483-3p in pancreatic cancer. Moreover, it has been reported that approximately 55% of pancreatic adenocarcinomas show inactivation of the Smad4/DPC4 gene by one of two mechanisms: homozygous deletion and loss of heterozygosity. However, the expression status of Smad4 and its correlation with miR483-3p are still unknown in adrenal cortical tumours. Therefore, we also evaluated the expression of Smad4 in all 50 tumours. We found that ‘diffusely positive’ expression in ACCs by real-time quantitative RT–PCR in 34 samples (10 primary ACCs and 24 ACAs).

| miR483-3p | IGF2 | Smad4 |
|----------|------|-------|
| Elevated | Negative/Low | $P$ | Elevated | Negative/Low | $P$ | Elevated | Negative/Low | $P$ |
| MiB1 | | | | | | | | |
| >5% | 12 | 4 | 0.394 | 9 | 7 | 0.401 | 2 | 14 | 0.520 |
| <5% | 5 | 4 | 7 | 2 | 0 | 9 |

Table 4. Correlation between miR483-3p, IGF2 or Smad4 expression and cellular proliferative activity

© 2013 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 64, 567–576.
Table 5. Clinical features and immunohistochemical results of the 15 borderline tumors

| Tumor no. | Sex | Age (years) | Tumor size (cm) | Tumor weight (g) | Tumor Location | Clinical symptom | Weiss score | MiR483-3p | IGF2 | Smad-4 | MIB-1 | Follow-up                     |
|-----------|-----|-------------|-----------------|-----------------|----------------|-----------------|-------------|-----------|------|-------|-------|-------------------------------|
| 1         | F   | 55          | 6               | 82              | Left           | No              | 3           | E         | N    | N     | L     | Relapse, DOD after 47 m       |
| 2         | M   | 49          | 5               | 70              | Right          | Cushing syndrome| 3           | E         | E    | E     | E     | NED after 90 m                |
| 3         | F   | 27          | 9               | 85              | Left           | No              | 3           | E         | E    | N     | H     | Metastases, DOD after 17 m    |
| 4         | F   | 26          | 5               | 33              | Right          | No              | 3           | E         | E    | E     | L     | NED after 58 m                |
| 5         | F   | 44          | 3               | 7               | Right          | Cushing syndrome| 3           | E         | E    | N     | L     | Relapse, DOD after 25 m       |
| 6         | F   | 29          | 4               | 27              | Right          | No              | 3           | N         | N    | E     | E     | NED after 45 m                |
| 7         | M   | 40          | 2               | 2               | Right          | No              | 2           | N         | E    | N     | L     | NED after 100 m               |
| 8         | M   | 58          | 4.5             | 30              | Left           | No              | 2           | N         | N    | N     | H     | LTFU                          |
| 9         | M   | 56          | 10              | 90              | Left           | No              | 2           | E         | N    | N     | L     | LTFU                          |
| 10        | F   | 52          | 5               | 23              | Right          | No              | 2           | N         | E    | E     | L     | NED after 99 m                |
| 11        | F   | 23          | 3               | 11              | Left           | Primary aldosterone syndrome | 2 | N | N | E | H | LTFU |
| 12        | F   | 52          | 3               | 12              | Right          | No              | 2           | N         | E    | E     | L     | NED after 84 m                |
| 13        | F   | 59          | 7               | 125             | Left           | No              | 2           | N         | N    | N     | N     | NED after 61 m                |
| 14        | F   | 56          | 5               | 64              | Right          | Primary aldosterone syndrome | 2 | E | N | E | H | LTFU |
| 15        | F   | 45          | 3               | 20              | Left           | No              | 2           | N         | N    | N     | L     | NED after 53 m                |

NED, No evidence of disease; DOD, dead of disease; LTFU, lost to follow-up; E, elevated; N, negative/low; H, high, >5%; L, low, <5%.
of Smad4 occurred in only two of 25 ACCs, with 23 of 25 ACCs showing ‘focally positive’ or ‘negative’ staining. According to Wilentz et al., cases known to have at least one wild-type Smad4 gene were expected to show diffusely positive expression of Smad4. Immunohistochemical staining for Smad4 labelled as ‘negative/low’ indicated deregulation of Smad4, regardless of the mechanism (i.e. overexpression of miR483-3p or the two types of gene inactivation). In our study, negative/low expression of Smad4 occurred in 23 of 25 ACCs, compared to 10 of 25 ACAs, a statistically significant difference. This suggests that down-regulation of Smad4 expression may play roles in the carcinogenesis of adrenocortical carcinoma. The mechanism underlying the role of miR483-3p and the down-regulation of Smad4 expression in the progression of adrenal cortical carcinomas still requires further biological investigation.

Proliferative activity measured by MIB-1 staining was reported in several previous studies to be useful for the diagnosis and prognostic assessment of ACCs. However, diagnostic accuracy was not verified. We tested MIB-1 expression in the same study cohort, and analysed its relationship with miR483-3p, IGF2 and Smad4 expression in ACCs. We found that 64% (16 of 25) ACCs had high expression of MIB1, compared to 4% (one of 25) of ACAs. However, the MIB1 expression level was not associated with miR483-3p, IGF2 or Smad4 expression in ACCs.

To validate further the differential diagnostic efficacy of the molecular markers and identify those that were most reliable, their expression was assessed in an independent set of 15 borderline tumours (Weiss score = 2 or 3), which were followed up for 42–103 months. The results showed that none of the four markers alone could predict malignant potential accurately. However, the combination of elevated expression of miR483-3p and negative/low expression of Smad4 could differentiate the three tumours that followed a malignant course from others.

Based on our finding that miR483-3p and Smad4 expression together could predict clinically malignant behaviour of borderline tumours, we further analysed the prognostic value of the two markers in carcinomas. The results indicated a trend towards ACC patients with tumours having elevated miR483-3p and negative/low Smad4 expression showing a worse disease outcome than other patients, although the association was not statistically significant. Thus, a larger sample size is needed to evaluate further the diagnostic and prognostic efficacy of the two markers.

In conclusion, our study confirmed that tumour size, tumour weight, hormonal function and the Weiss system can differentiate malignant from benign tumours in most cases. The combined use of miR483-3p and Smad4 immunohistochemistry provides a helpful additional tool to the Weiss systems in borderline cases. However, larger sample sizes are needed to determine further the differential diagnostic and prognostic efficacy of miR483-3p and Smad4 expression. Moreover, the mechanisms through which miR483-3p modulates the development of adrenal cortical carcinoma remain to be clarified in future biological studies.

Acknowledgements
We are grateful to Dr Jing Zhang for helping to review the Weiss system. This study was supported by The National Nature Science Foundations of China (30973470 and 81172334).

Conflict of interest
The authors declare no conflicts of interest.

References
1. Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Ann. Intern. Med. 2003; 138: 424–429.
2. Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinoma: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg. 2001; 25: 891–897.
3. Favia G, Lumachi F, Carraro P, D’Amico DF. Adrenocortical carcinoma. Our experience. Minerva Endocrinol. 1995; 20: 95–99.
4. Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88: 711–736.

© 2013 The Authors. Histopathology Published by John Wiley & Sons Ltd. Histopathology, 64, 567–576.
576 C. Wang et al.

5. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984; 8: 163–169.

6. Weiss LM, Medeiros LJ, Vickery AI, Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 1989; 13: 202–206.

7. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathological and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002; 26: 1612–1619.

8. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001; 61: 6762–6767.

9. Lucon AM, Pereira MA, Mendonca BB et al. Adrenocortical tumors: results of treatment and study of Weiss’s score as a prognostic factor. Rev. Hosp. Clin. Fac. Med. Sao Paulo 2002; 57: 251–256.

10. Klibanski A, Stephen AE, Greene MF et al. Comparative histologic study of 43 metastasizing tumors: results of treatment and study of Weiss’s score as a prognostic factor. Am. J. Surg. 1989; 169: 145–150.

11. Pohlink C, Tannapfe A, Eichfeld U et al. Immunohistochemical expression of p53, p21, and p16 in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 1998; 83: 1034–1039.

12. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat stress, and timing. Cell 2003; 113: 673–676.

13. Veronese A, Lupini L, Consiglio J et al. Immunohistochemical study of DPC4 expression in adrenocortical adenomas and carcinomas. J. Endocrinol. Invest. 1999; 22: 335–341.

14. Giordano TJ, Thomas DG, Kuick R et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003; 162: 521–531.

15. Hahn SA, Hoque AT, Moskaluk CA et al. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117: 1630–1639.

16. Schutte M, Hruban RH, Hedrick L et al. Microarray gene expression profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117: 1630–1639.

17. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008; 12: 2171–2176.

18. Meyer-Rochow GY, Jackson NE, Conaglen JV et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr. Relat. Cancer 2010; 17: 835–846.

19. Soon PS, Gill AJ, Benn DE et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adrenocortical adenomas. Endocr. Relat. Cancer 2009; 16: 573–583.

20. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenosarcomas: a new marker of DPC4 inactivation. Am. J. Pathol. 2000; 156: 37–43.

21. Gupta D, Shidham V, Holden J et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl. Immunohistochem. Mol. Morph. 2001; 9: 215–221.

22. Nakazumi H, Sasano H, Iino K et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod. Pathol. 1998; 11: 1165–1170.

23. Wachenfeld C, Beuschlein F, Zwerdling O et al. Discrimining malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol. 2001; 145: 335–341.

24. Schmitt A, Saremaslani P, Schmid S et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006; 49: 298–307.

25. Lewinsky BS, Grigor KM, Symington T, Neville AM. The clinical and pathologic features of ‘non-hormonal’ adrenocortical tumors: report of twenty new cases and review of the literature. Cancer 1974; 33: 778–790.

26. Tang CK, Gray GF. Adrenocortical neoplasms. Prognosis and morphology. Urolgy 1975; 5: 691–695.

27. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 6: 972–980.

28. Sasano H, Suzuki T, Moriya T. Recent advances in surgical pathology of adenal incidentaloma. Biomed. Pharmacother. 2000; 54: 169–174.

29. Dackiw AP, Lee JE, Gage RF, Evans DB. Adrenal cortical carcinoma. World J. Surg. 2001; 25: 914–926.

30. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adren al tumors: an institutional perspective. Surgery 1991; 110: 1014–1021.

31. Giordano TJ. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr. Pathol. 2006; 17: 355–363.

32. Patterson EE, Holloway AK, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117: 1630–1639.

33. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 2009: 60: 167–179.

34. Logié A, Boulle N, Gaston V et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol. 1999; 23: 23–32.

35. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–353.

36. Hahn SA, Hoose AT, Moskaluk CA et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996; 56: 490–494.

37. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types. Cancer Res. 1996; 56: 2527–2530.

Supporting information

Additional supporting information may be found in the online version of this article:

Table S1. The morphological features of the 15 borderline tumours.

Table S2. Relationship between expression of miR483-3p and IGF2, and miR483-3p and Smad4 in adrenocortical carcinomas.

Table S3. Correlations between clinicopathological variables and expression of miR483-3p and IGF2 in adrenocortical carcinomas.

Table S4. Clinicopathological features of the two adrenocortical carcinoma patients with strong Smad4 staining.